BIOPALETTE
LIVE

Serial Number

79242171

Owner

Bio Palette Co., Ltd.

Attorney

Geoffrey K Pechie

Filing Date

Jan 9, 2018

Add to watchlist:

No watchlists yet
View on USPTO

BIOPALETTE Trademark

Serial Number: 79242171 • Registration: 5778150

BIOPALETTE is a trademark filed by Bio Palette Co., Ltd. on January 9, 2018. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 31 (Natural Agricultural Products). The application is currently registered and active.

Owner Contact Info

Bio Palette Co., Ltd. (6 trademarks)

6-1, Otemachi 1-chome
Chiyoda-ku 100-0004 , JP

Entity Type: 03

Trademark Details

Filing Date

January 9, 2018

Registration Date

June 18, 2019

Published for Opposition

April 2, 2019

Cancellation Date

January 6, 2026

Goods & Services

Chemicals for use in industry and science; chemical reagents for use in genetic research other than for medical or veterinary purposes; chemical reagents for use in genetic research in the field of genome or gene editing other than for medical or veterinary purposes; chemical substances produced by genome or gene editing operation for analyses in laboratories, other than for medical or veterinary purposes; chemical reagent for separation and production of gene editing substances for non-medical purposes; biotechnologically-formed genes for use in the manufacture of agricultural seeds produced by genome or gene editing operation; cultures of microorganisms produced by genome or gene editing operation, other than for medical or veterinary use; diagnostic reagents for scientific or research use in the field of genome or gene editing; biotechnologically-formed genes for use in the manufacture of agricultural seeds; cultures of microorganisms, other than for medical or veterinary use

Living cells, microorganisms, proteins, peptides, nucleic acid sequences, and combinations thereof for medical diagnosis or veterinary diagnosis purposes; pharmaceutical preparations produced by genome or gene editing operation for treatment of genetic diseases; pharmaceutical preparations produced by genome or gene editing operation for modifying human microbiome; chemical reagents for medical purposes produced by genome or gene editing operation; chemical reagents for medical purposes in the field of genome or gene editing operation; cultures of microorganisms for medical or veterinary use produced by genome or gene editing operation; living cells, microorganisms, proteins, peptides, nucleic acid sequences, and combinations thereof for medical or veterinary purposes produced by genome or gene editing operation; biological cells for surgical implantation produced by genome or gene editing operation; pharmaceutical and biological preparations, and diagnostic products based on gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for use in treatment of genetic diseases; pharmaceutical and biological preparations, and diagnostic products based on gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for use in treatment of cancer; pharmaceutical and biological preparations, and diagnostic products based on gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for use in modifying human microbiome; cultures of microorganisms for medical or veterinary purposes; biological tissue cultures for medical or veterinary purposes * all of the foregoing [ other than those ] produced by genome or gene editing operation *

Research and development in the field of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the field of genetics and genetic engineering; DNA screening for scientific research purposes; scientific and technological services, namely, research and development, quality control, and technical advisory services relating thereto in the fields of protein, antibody, and microorganism study, and the study of cells; structural and functional analysis of the genome with genome editing technology; DNA screening for scientific research purposes with genome editing technology; scientific and technological services, namely, research, development, technical advisory services, and information technology services, all relating to genome editing technology; scientific and technological services, namely, research and development, quality control, and technical advisory services relating thereto in the fields of protein, antibody, and microorganism study, and the study of cells, all with genome editing technology; scientific research and development in the field of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems with genome editing technology; scientific research in the field of genetics and genetic engineering with genome editing technology; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs, all with genome editing technology; development of pharmaceuticals, cosmetics or foodstuffs, all with genome editing technology; technical advisory services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome editing technology; information technology services relating to the development of pharmaceuticals, cosmetics or foodstuffs, all with genome editing technology; testing, inspection or research relating to medical treatment or medical technology with genome editing technology; information technology services for testing, inspection or research relating to medical treatment or medical technology with genome editing technology; testing or research relating to genome or gene to which genome editing technology is applied; scientific and medical research and survey in relation to bioinformatic tools in the fields of editing, modulation, modification, engineering, regulation, repair and therapy of gene, genome and cells to develop human pharmaceutical, biological preparations, and diagnostic products and services; scientific and technical research and development of bioinformatic tools in the fields of editing, modulation, modification, engineering, regulation, repair and therapy of gene, genome and cells to develop human pharmaceutical, biological preparations, and diagnostic products and services; research and development for the pharmaceutical industry and biotechnology industry with genome editing technology; research and development of biotechnology for others; research and development of genome editing technology for others; development of pharmaceutical preparations and medicines; biotechnology research; research and development in the field of genomics and biotechnology; technical advisory services in the field of genomics and biotechnology; structural and functional analysis of genomes; scientific and medical research in the fields of gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy to develop human pharmaceutical and biological preparations to be delivered or applied ex vivo to human cells for use in human therapeutics and diagnostic products and services; scientific study and research in the fields of gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy to develop human pharmaceutical and biological preparations to be delivered or applied ex vivo to human cells for use in human therapeutics and diagnostic products and services; design of bioinformatic algorithms and models for use in scientific and medical research in the fields of gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy to develop human pharmaceutical and biological preparations to be delivered or applied ex vivo to human cells for use in human therapeutics and diagnostic products and services; laboratory research in the field of pharmaceuticals; conducting clinical trials for others in the field of pharmaceuticals; laboratory research in the field of gene expression; research and development services in the field of gene expression systems; research and development services in the field of microorganisms and cells; scientific research services in the field of genetic engineering relating to plants

Crop seeds; plant seeds; crop seeds produced by genome or gene editing operation; plant seeds produced by genome or gene editing operation; crop seeds in which herbicide tolerance genes are incorporated by genome or gene editing operation; plant seeds in which herbicide tolerance genes are incorporated by genome or gene editing operation; vegetable seeds for planting produced by genome or gene editing operation; seeds for agricultural purposes; vegetable seeds for planting; seeds for planting; genetically modified seeds including seeds for agricultural purposes, flower seeds, seeds for planting, or vegetable seeds for planting

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Jan 22, 2026 DENA
DEATH OF INTERNATIONAL REGISTRATION
Jan 22, 2026 DETH
CANCELLED SECTION 71
Jan 2, 2026 C71T
CHANGE OF NAME/ADDRESS REC'D FROM IB
Mar 28, 2025 ADCH
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jun 18, 2024 REM3
CHANGE OF NAME/ADDRESS REC'D FROM IB
Mar 18, 2023 ADCH
NEW REPRESENTATIVE AT IB RECEIVED
Jul 30, 2022 NREP
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Jun 9, 2021 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Jun 6, 2021 INPR
CANCELLATION TERMINATED NO. 999999
Sep 30, 2020 CANT
AMENDMENT UNDER SECTION 7 - PROCESSED
Sep 24, 2020 A7OK
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 24, 2020 APRE
CANCELLATION DENIED NO. 999999
Sep 24, 2020 CAND
AMENDMENT UNDER SECTION 7 - PROCESSED
Jul 23, 2020 A7OK
REGISTERED - SEC. 7 REQUEST ABANDONED
May 18, 2020 PRA7
POST REGISTRATION ACTION MAILED - SEC. 7
May 18, 2020 PRAM
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 5, 2020 APRE
TEAS SECTION 7 REQUEST RECEIVED
Apr 8, 2020 ES7R
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 18, 2019 FINO
CANCELLATION INSTITUTED NO. 999999
Oct 9, 2019 PETC
FINAL DISPOSITION NOTICE SENT TO IB
Sep 28, 2019 FICS
FINAL DISPOSITION PROCESSED
Sep 28, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 18, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 18, 2019 R.PR
PUBLISHED FOR OPPOSITION
Apr 2, 2019 PUBO
NOTICE OF PUBLICATION
Mar 13, 2019 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 28, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 27, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 27, 2019 CRFA
ASSIGNED TO LIE
Feb 27, 2019 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 22, 2019 TROA
REFUSAL PROCESSED BY IB
Nov 24, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 7, 2018 RFCS
REFUSAL PROCESSED BY MPU
Nov 7, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 24, 2018 RFCR
NON-FINAL ACTION WRITTEN
Oct 23, 2018 CNRT
APPLICATION FILING RECEIPT MAILED
Oct 16, 2018 MAFR
ASSIGNED TO EXAMINER
Oct 10, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 10, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 4, 2018 REPR